Glucagon-Like Peptide-1 Receptor Agonists and Anesthesia-Are We Clearer on the Correct Approach?
作者信息
Bloomgarden Zachary
机构信息
Department of Medicine, Division of Endocrinology, Diabetes and Bone Disease, Icahn School of Medicine, Mount Sinai, New York, USA.
出版信息
J Diabetes. 2024 Dec;16(12):e70041. doi: 10.1111/1753-0407.70041.
Abstract
摘要
相似文献
1
Glucagon-Like Peptide-1 Receptor Agonists and Anesthesia-Are We Clearer on the Correct Approach?胰高血糖素样肽-1受体激动剂与麻醉——我们对正确方法更清楚了吗？
J Diabetes. 2024 Dec;16(12):e70041. doi: 10.1111/1753-0407.70041.
2
Glucagon-like peptide-1 receptor agonists: a narrative review of clinical pharmacology and implications for peri-operative practice.胰高血糖素样肽-1 受体激动剂：临床药理学的叙述性综述及其对围手术期实践的影响。
Anaesthesia. 2024 Jul;79(7):735-747. doi: 10.1111/anae.16306. Epub 2024 May 13.
3
Effect of glucagon-like peptide-1 receptor agonists in subjects with type 2 diabetes mellitus: A meta-analysis.胰高血糖素样肽-1 受体激动剂在 2 型糖尿病患者中的作用：一项荟萃分析。
J Clin Pharm Ther. 2021 Dec;46(6):1650-1658. doi: 10.1111/jcpt.13502. Epub 2021 Aug 5.
4
Incretin-based therapies for type 2 diabetes mellitus: a review of direct comparisons of efficacy, safety and patient satisfaction.基于肠降血糖素的 2 型糖尿病治疗药物：对疗效、安全性和患者满意度的直接比较的综述。
Int J Clin Pharm. 2013 Apr;35(2):159-72. doi: 10.1007/s11096-012-9729-9. Epub 2012 Dec 22.
5
Repositioning of dipeptidyl peptidase-4 inhibitors and glucagon like peptide-1 agonists as potential neuroprotective agents.将二肽基肽酶-4抑制剂和胰高血糖素样肽-1激动剂重新定位为潜在的神经保护剂。
Neural Regen Res. 2019 May;14(5):745-748. doi: 10.4103/1673-5374.249217.
6
Glucagon-like peptide-1 receptor agonist use in pregnancy: a review.胰高血糖素样肽-1受体激动剂在妊娠中的应用：综述
Am J Obstet Gynecol. 2025 Jan;232(1):17-25. doi: 10.1016/j.ajog.2024.08.024. Epub 2024 Aug 23.
7
Glucagon-like peptide 1 (GLP-1) receptor agonists' use during pregnancy: Safety data from regulatory clinical trials.胰高血糖素样肽1（GLP-1）受体激动剂在孕期的使用：来自监管临床试验的安全性数据。
Diabetes Obes Metab. 2025 May 6. doi: 10.1111/dom.16437.
8
Blood pressure lowering efficacy of dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 (GIP/GLP-1) receptor agonists compared to glucagon-like peptide-1 (GLP-1) receptor agonists.与胰高血糖素样肽-1（GLP-1）受体激动剂相比，双重葡萄糖依赖性促胰岛素多肽/胰高血糖素样肽-1（GIP/GLP-1）受体激动剂的降压疗效
Cochrane Database Syst Rev. 2025 Apr 16;4(4):CD016144. doi: 10.1002/14651858.CD016144.
9
Rates of glucagon-like peptide-1 receptor agonist use and aspiration events associated with anesthesia at a Canadian academic teaching centre.加拿大一所学术教学中心使用胰高血糖素样肽-1受体激动剂的比率以及与麻醉相关的误吸事件。
Can J Anaesth. 2024 May;71(5):673-675. doi: 10.1007/s12630-024-02761-x. Epub 2024 Apr 8.
10
Glucagon-like peptide-1 receptor agonists decrease hyperinsulinemia and hyperandrogenemia in dehydroepiandrosterone-induced polycystic ovary syndrome mice and are associated with mitigating inflammation and inducing browning of white adipose tissue†.胰高血糖素样肽-1 受体激动剂可降低脱氢表雄酮诱导的多囊卵巢综合征小鼠的高胰岛素血症和高雄激素血症，并与减轻炎症和诱导白色脂肪组织棕色化有关。
Biol Reprod. 2023 Jun 9;108(6):945-959. doi: 10.1093/biolre/ioad032.
本文引用的文献
1
Multisociety clinical practice guidance for the safe use of glucagon-like peptide-1 receptor agonists in the perioperative period.围手术期安全使用胰高血糖素样肽-1受体激动剂的多学会临床实践指南。
Surg Obes Relat Dis. 2024 Dec;20(12):1183-1186. doi: 10.1016/j.soard.2024.08.033. Epub 2024 Oct 29.
2
Perioperative Management of Patients Taking Glucagon-like Peptide-1 Receptor Agonists: Applying Evidence to Clinical Practice.使用胰高血糖素样肽-1受体激动剂患者的围手术期管理：将证据应用于临床实践
Anesthesiology. 2024 Dec 1;141(6):1141-1161. doi: 10.1097/ALN.0000000000005204.
3
Preprocedure Care of Patients on Glucagon-like Peptide-1 Receptor Agonists: A Multisociety Clinical Practice Guidance.胰高血糖素样肽-1受体激动剂治疗患者的术前护理：多学会临床实践指南
Anesthesiology. 2024 Dec 1;141(6):1208-1209. doi: 10.1097/ALN.0000000000005231.
4
Glucagon-like peptide-1 receptor agonists and aspiration risk.胰高血糖素样肽-1受体激动剂与误吸风险。
BMJ. 2024 Oct 22;387:q1986. doi: 10.1136/bmj.q1986.
5
Glucagon-like peptide-1 receptor agonists before upper gastrointestinal endoscopy and risk of pulmonary aspiration or discontinuation of procedure: cohort study.上消化道内镜检查前应用胰高血糖素样肽-1 受体激动剂与发生吸入性肺炎或中止操作的风险：队列研究。
BMJ. 2024 Oct 22;387:e080340. doi: 10.1136/bmj-2024-080340.
6
Clinical Consequences of Delayed Gastric Emptying With GLP-1 Receptor Agonists and Tirzepatide.胰高血糖素样肽-1受体激动剂和替尔泊肽导致胃排空延迟的临床后果
J Clin Endocrinol Metab. 2024 Dec 18;110(1):1-15. doi: 10.1210/clinem/dgae719.
7
The impact of glucagon-like peptide-1 receptor agonists in the patients undergoing anesthesia or sedation: systematic review and meta-analysis.胰高血糖素样肽-1受体激动剂对接受麻醉或镇静患者的影响：系统评价与荟萃分析
Perioper Med (Lond). 2024 Jul 22;13(1):78. doi: 10.1186/s13741-024-00439-y.
8
Glucagon-Like Peptide-1 Receptor Agonists Do Not Increase Aspiration During Upper Endoscopy in Patients With Diabetes.胰高血糖素样肽-1受体激动剂不会增加糖尿病患者上消化道内镜检查期间的误吸风险。
Clin Gastroenterol Hepatol. 2025 Apr;23(5):739-747. doi: 10.1016/j.cgh.2024.04.038. Epub 2024 May 15.
9
Risks of peri- and postoperative complications with glucagon-like peptide-1 receptor agonists.胰高血糖素样肽-1 受体激动剂的围手术期并发症风险。
Diabetes Obes Metab. 2024 Aug;26(8):3128-3136. doi: 10.1111/dom.15636. Epub 2024 May 14.
10
Preoperative GLP-1 Receptor Agonist Use and Risk of Postoperative Respiratory Complications.术前使用胰高血糖素样肽-1受体激动剂与术后呼吸并发症风险
JAMA. 2024 May 21;331(19):1672-1673. doi: 10.1001/jama.2024.5003.
Zotero 插件